Stenkem Molecules Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-06-2024
- Paid Up Capital ₹ 1.00 M
as on 25-06-2024
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 60.69%
(FY 2022)
- Profit 57.71%
(FY 2022)
- Ebitda -24.45%
(FY 2022)
- Net Worth 21.91%
(FY 2022)
- Total Assets 43.46%
(FY 2022)
About Stenkem Molecules
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Sachin Ahuja, Rajesh Kumar, Sangeeta Rani, and One other member serve as directors at the Company.
- CIN/LLPIN
U24303HR2018PTC075659
- Company No.
075659
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Sep 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Karnal, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Stenkem Molecules Private Limited offer?
Stenkem Molecules Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Capsules, Animal Medicines & Health Care, Veterinary Medicines, Ayurvedic,Herbal Products & Medicine, Ayurvedic Herbal Syrups & Tonics, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Anti Infective Drugs & Medicines, Antibacterial Drugs.
Who are the key members and board of directors at Stenkem Molecules?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sachin Ahuja  | Director | 20-Jan-2022 | Current |
| Rajesh Kumar | Director | 11-Sep-2018 | Current |
| Sangeeta Rani | Director | 01-Mar-2022 | Current |
| Pooja Ahuja | Director | 20-Jan-2022 | Current |
Financial Performance of Stenkem Molecules.
Stenkem Molecules Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 60.69% increase. The company also saw a substantial improvement in profitability, with a 57.71% increase in profit. The company's net worth Soared by an impressive increase of 21.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stenkem Molecules?
In 2019, Stenkem Molecules had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Semmax Printing Private LimitedActive 5 years 10 monthsRajesh Kumar and Sangeeta Rani are mutual person
- Stenkem Biolife Private LimitedActive 2 years 12 days
Rajesh Kumar and Sangeeta Rani are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Stenkem Molecules?
Unlock and access historical data on people associated with Stenkem Molecules, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stenkem Molecules, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stenkem Molecules's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
